Evaluation of 'cypenhymustine', a new anticancer compound, in murine tumour models.

Abstract

'Cypenhymustine', 3-[2-[bis(2'-chloroethyl)-amino] ethyl]-5,5- tetramethylenehydantoin, has been synthesised as a potential analog of spiromustine (NSC 172112). The LD50 value was determined in Swiss male mice and found to be 65.0 mg/kg by single i.p. injection. In in vivo screening experiments, three parameters, namely, ascites cell count, ascites fluid measurement and increase in life span (ILS) of drug-treated over control Swiss mice were studied in three murine ascites tumours namely Ehrlich ascites carcinoma (EAC), sarcoma-180 (S-180) and Dalton's lymphoma (DL). Cypenhymustine exhibited a very high percentage of inhibition of both the ascites cell and fluid in these models and also displayed excellent reproducible ILS activity (ILS values of 151 in EAC, 157 in S-180 and 181 in DL at the optimum dose of 3 mg/kg for days 1-7 treatment following tumour transplant on day 0) having a 'curative' effect (1-2 animals: 6 having > 60 days survival rate). The chemical alkylating activity has been compared with spiromustine and another antitumour agent namely nor-HN2.

• Authors: U Sanyal, S Bhattacharya, U Sadhu, S Dutta, H Das, M Ghosh
• Journal: Cancer letters (Cancer Lett) Vol. 70 Issue 1-2 Pg. 1-6 (Jun 15 1993) ISSN: 0304-3835 [Print] Ireland
• PMID: 8330289 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Hydantoins
• Nitrogen Mustard Compounds
• cypenhymustine

Topics

• Animals
• Antineoplastic Agents (chemical synthesis, therapeutic use)
• Carcinoma, Ehrlich Tumor (drug therapy)
• Dose-Response Relationship, Drug
• Drug Screening Assays, Antitumor
• Hydantoins (chemical synthesis, therapeutic use)
• Lethal Dose 50
• Lymphoma (drug therapy)
• Male
• Mice
• Mice, Inbred Strains
• Nitrogen Mustard Compounds (chemical synthesis, therapeutic use)
• Sarcoma 180 (drug therapy)